Extracorporeal Shock Wave Lithotripsy (ESWL) for renal and ureteral stones
Customize your policy alerts
Sign up for all Kaiser Permanente policy alerts
Know when Kaiser Permanente releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical review criteria that define medical necessity and authorization requirements for ESWL in adult Kaiser Permanente members in Washington; applies to both Medicare and non‑Medicare members covered by Kaiser Foundation Health Plan of Washington.
Adopted criteria for Extracorporeal Shock Wave Lithotripsy (ESWL) for Medicare and non‑Medicare members, effective 02/01/2026.
Specific size- and location-based criteria for ureteral stones (including trial of medical expulsive therapy durations) were defined for ESWL coverage.
Renal stone criteria added specifying total stone burden <20 mm or not a candidate for PCNL/URS, and requirement that stone be radiopaque on plain radiograph.
A recommendation that retreatment with ESWL within 12 months is not recommended and definitive therapy with cystourethroscopy is preferred.
Coverage Criteria for ESWL
Ureteral Stones — Initial Therapy
Covered when ALL of the following are met:
Ureteral ESWL criteria
- Stone is visible on plain radiograph (radiopaque).
Medical expulsive therapy (MET) requirement
- For stones 4–6 mm: completed ≥2 weeks of MET with alpha blockers unless intolerant or contraindicated.
- For stones <4 mm: completed ≥4 weeks of MET with alpha blockers unless intolerant or contraindicated.
- For stones in the mid to distal ureter, ureteroscopy (URS) is preferred; ESWL will only be considered if a rationale is provided explaining why URS is not being pursued.
Renal Stones — Initial Therapy
Covered when ALL of the following are met:
Renal ESWL criteria
- Total stone burden is less than 20 mm OR the patient is not a candidate for percutaneous nephrolithotomy (PCNL) or ureteroscopy (URS).
- Stone is visible on plain radiograph (radiopaque).
ESWL is contraindicated in several clinical situations. Do not use ESWL for suspected cystine or uric acid stones; ureteroscopy (URS) is the recommended alternative. ESWL should also be avoided for a solitary lower pole renal stone larger than 10 mm unless percutaneous nephrolithotomy (PCNL) or URS have already failed or are contraindicated. Active, untreated urinary tract infections are a contraindication, and prior ESWL that failed to treat the current stone is also listed as a reason to withhold repeat ESWL.
Retreatment with ESWL for the same stone within 12 months is generally not recommended and is considered a relative contraindication because ESWL has a higher retreatment rate than cystourethroscopy. When repeat therapy is being considered within this interval, the policy prefers a more definitive procedure; cystourethroscopy (definitive therapy) is recommended instead. For operational practice, document prior ESWL history and provide rationale if retreatment is requested within 12 months, and expect prior authorization review to favor definitive endoscopic management over repeat ESWL.
Coding and Billing
| 50590 | Lithotripsy, extracorporeal shock wave |
Provider Actions, Authorization, and Documentation
Prior authorization required for ESWL (CPT 50590)
Prior authorization is required for Extracorporeal Shock Wave Lithotripsy (ESWL) CPT code 50590. Requests must include supporting clinical documentation demonstrating the service meets the policy's medical necessity criteria.
- CPT 50590 (Lithotripsy, extracorporeal shock wave) is subject to authorization when criteria apply.
- Include documentation described in the policy to support medical necessity (see Required documentation).
Trial of MET (alpha blocker) required before ESWL for ureteral stones
For ureteral stones, a trial of medical expulsive therapy (MET) with an alpha blocker must be completed before ESWL is considered, with required durations differing by stone size.
- Stones 4–6 mm: at least 2 weeks of MET with an alpha blocker unless not tolerated or contraindicated.
- Stones <4 mm: at least 4 weeks of MET with an alpha blocker unless not tolerated or contraindicated.
- For mid to distal ureter stones, URS is preferred and ESWL will only be considered if the request provides rationale why URS is not being pursued.
Required clinical documentation (last 6 months)
Submit the most recent clinical notes (within the last 6 months) from the requesting provider and/or specialist to support medical necessity for ESWL.
- Include the last 6 months of clinical notes from the requesting provider and/or specialist as part of the authorization request.
Denial risk — contraindications and retreatment
Requests may be denied if contraindications or prior-failure/retreatment scenarios are present; review contraindications and retreatment guidance before submitting.
- Suspected cystine or uric acid stones (URS is recommended) — may lead to denial.
- Single lower pole stone >10 mm unless PCNL and/or URS have failed or are contraindicated.
- Untreated active urinary tract infection.
- Prior ESWL that failed to treat the current stone.
- Requesting ESWL retreatment within 12 months (retreatment within 12 months is not recommended and is considered relatively contraindicated; definitive therapy with cystourethroscopy is recommended).
Definitions
Background
Extracorporeal Shock Wave Lithotripsy (ESWL) delivers focused pulsed energy (shock waves) through the body to fragment urinary stones so that residual fragments can pass in the urine. ESWL is intended for adult patients when stone characteristics and patient factors permit safe targeting and fragment passage. General contraindications include pregnancy, uncontrolled bleeding diathesis or untreated coagulopathy, and active, untreated urinary tract infection; ESWL should also be avoided when patient anatomy or distal obstruction prevents safe shockwave targeting or fragment clearance.
Revision History
Policy adoption: ESWL criteria (ureteral and renal) became effective; Medicare and non‑Medicare adoption per MPC approval.
Medical Policy Committee (MPC) approved adoption of criteria for Extracorporeal Shock Wave Lithotripsy (ESWL) and required 60-day notice prior to effective date.
Added recommendation that ESWL retreatment within 12 months is not recommended and is considered relatively contraindicated; definitive therapy with cystourethroscopy is recommended.
Defined ureteral stone size- and location-based criteria including MET duration requirements and URS preference for mid-to-distal ureter; added renal stone criteria requiring total stone burden <20 mm and radiopacity.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.